Form 4: Beta Bionics CFO Sells Shares Under 10b5-1 Plan

Beta Bionics, Inc. (BBNX) Chief Financial Officer, Stephen Feider, reported transactions involving the sale of company common stock and the acquisition of stock options under a pre-arranged trading plan.

Summary

• Stephen Feider, CFO of Beta Bionics, Inc., executed several transactions on June 26 and June 29, 2026.
• These transactions involved the sale of common stock and the acquisition of employee stock options.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on May 15, 2025.
• Feider acquired 4,982 shares on June 26, 2026, at a price of $5.10 per share, and an additional 4,896 shares on June 29, 2026, also at $5.10 per share.
• Concurrently, Feider sold 5,104 shares on June 26, 2026, at a weighted average price of $17.0467, and 4,896 shares on June 29, 2026, at a weighted average price of $17.0304.
• Following these transactions, Feider beneficially owns 170,827 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the CFO is selling shares, it is conducted under a pre-established 10b5-1 plan, mitigating concerns of insider trading. The sale price is significantly higher than the option exercise price, indicating a profitable transaction for the executive.

Positives

• The sales were executed under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies designed to avoid insider trading concerns.
• The acquisition of employee stock options suggests continued participation in the company's equity incentive program.

Negatives

• The CFO sold a significant number of shares, which could be interpreted negatively by the market, despite being part of a pre-planned strategy.
• The sale price of the stock ($17.03-$17.04) is considerably higher than the acquisition price of the options ($5.10), indicating a substantial profit for the CFO on these transactions.

Risks

• The sale of shares by a key executive, even under a 10b5-1 plan, may signal a lack of confidence in near-term stock performance to some investors.
• The company's stock price could be negatively impacted by the perception of insider selling.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12.
• The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08.
• The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for publicly traded companies and report changes in beneficial ownership by insiders. The use of Rule 10b5-1 plans is a common strategy for executives to diversify their holdings or manage personal finances without triggering insider trading concerns, especially during periods of stock price appreciation.

Stakeholder Impact

• Shareholders may perceive the CFO's stock sales, even under a 10b5-1 plan, as a potential negative signal, possibly influencing short-term stock price movement.
• Employees holding stock options may view the CFO's continued participation in option grants positively, aligning executive incentives with company performance.

Next Steps

• Continued monitoring of insider transactions for Beta Bionics, Inc.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Stock Options, Beneficial Ownership, Beta Bionics, BBNX, Stephen Feider, CFO, Securities Transaction